Comparison of Analgesic Efficacy of PENB Block with FICB in Post Operative Hip Fracture Patients
NCT ID: NCT05810012
Last Updated: 2025-02-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
50 participants
INTERVENTIONAL
2022-04-01
2022-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Pericapsular Nerve Group Block
NCT05154318
Comparing Postoperative Pain After Pericapsular Nerve Block and Fascia Iliaca Block in Total Hip Arthroplasty
NCT06003738
Comparing Fascia Iliaca Compartment Block and Pericapsular Nerve Group Block for Hip Fracture Pain Control
NCT04210700
Comparison of PENG Block and FICB in Hip Fracture Patients
NCT04677348
Quality of Recovery After Hip Fracture Surgery: US-guided PENG Block Versus FICB
NCT05968014
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PENG Block Group
PENG block
10ml of 0.125% isobaric bupivacaine injected
FICB Group
FICB Block
20ml of 0.125% isobaric bupivacaine injected
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PENG block
10ml of 0.125% isobaric bupivacaine injected
FICB Block
20ml of 0.125% isobaric bupivacaine injected
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* bleeding disorders
* morbid obesity with BMI more than 35
* patients of chronic pain
* drug addiction
* psychiatric issues
30 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pain Medicine Department
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Moazzam Ali
Consultant Pain Specialist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Moazzam Ali
Role: PRINCIPAL_INVESTIGATOR
Pain Medicine Department
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pain Medicine Department
Lahore, , Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Comparison PENG versus FICB
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.